#	Pagina
attuale pagina	/open-h2020/projects/218129/index.html
-1	/open-h2020/per-topic/vinification/list/index.html
-2	/open-consip/fornitori/2021/profilo-09161970968/index.html
-3	/open-h2020/per-topic/goniometer/list/index.html
-4	/open-h2020/projects/227355/index.html
-5	/open-h2020/projects/218951/index.html
-6	/open-h2020/projects/222782/index.html
-7	/open-h2020/per-topic/rage/list/index.html
-8	/open-h2020/projects/193340/index.html
-9	/open-h2020/projects/223871/index.html
-10	/open-h2020/projects/225076/index.html

Opendata, web and dolomites

KlotoDx

KlotoDx A quick and cost-effective near-patient tool to identify sepsis-related bacteria and antibiotic resistances

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

KlotoDx project word cloud

Explore the words cloud of the KlotoDx project. It provides you a very rough idea of what is the project "KlotoDx" about.

expressed resistance spectrum cutting mostly causing time first near disease total enter moirai intelligence segment day place techniques death blood commercialize limited antibiotic bacterial fast feasibility leukemia adapt solution diagnosed promyelocytic detected identification characterization rates artificial agents apl house caused opportunity edge broad diagnosis treatment aand diagnostics manner lethal primary culture patients hours 24 genes validated bacteria engineering envision sme device diagnostic healthcare resistances efficient appropriately sepsis acute once 30 instrument ribosomal detect preliminary rna biodesign market efficiency people platform klotodx patient antibiotics plan generation investment worldwide reduce takes algorithms perform 70 boosts 6m dramatically disruptive validate antimicrobial detection care

Project "KlotoDx" data sheet

The following table provides information about the project.

Coordinator	MOIRAI BIODESIGN S.L. Organization address address: GRAN VIA CORTS CATALANES, 272, 8 4 city: BARCELONA postcode: 8004 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	http://www.moiraibiodesign.com/index.html
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2018
Duration (year-month-day)	from 2018-09-01 to 2018-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	MOIRAI BIODESIGN S.L. MOIRAI BIODESIGN S.L. Organization address address: GRAN VIA CORTS CATALANES, 272, 8 4 city: BARCELONA postcode: 8004 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	coordinator	50˙000.00

Map

Project objective

Sepsis is a common disease caused mostly by bacteria that affects about 30 M people each year worldwide. If not diagnosed on time and treated appropriately, it may be lethal in 30% of cases and the cost for the healthcare system if not detected within the first 24 hours can rise dramatically. Current diagnostic techniques used to detect bacteria in patients’ blood, and identify their antimicrobial resistances, are still based on blood culture which takes more than 1 day and has a very limited detection efficiency. Moirai Biodesign is currently engineering a whole new generation of RNA-based diagnostics using both our in-house and cutting-edge artificial intelligence algorithms to detect ribosomal RNA from bacterial agents and expressed bacterial genes associated to common antibiotic resistances and a patient’s blood sample. Our platform is a near-patient, fast, efficient and cost-effective solution for the early detection and characterization of sepsis-related bacteria which will improve patient’s treatment, avoid broad-spectrum antibiotics’ side-effects and dramatically reduce death rates. Our technology has been preliminary validated for the diagnosis of Acute Promyelocytic Leukemia (APL) and KlotoDx’s main goal is to further adapt, validate and commercialize our disruptive diagnosis device for the identification of sepsis-causing bacteria and their antibiotic resistance genes. To achieve it and place our disruptive near-patient solution in the healthcare market, we envision a total investment of around €2.3 M and we plan to reach the 70% (around €1.6M) by applying for a Phase 2 within the H2020 SME-Instrument programme, once we perform the feasibility study during Phase 1. The increasing need for early sepsis diagnosis aand its characterization in terms of antibiotic resistance boosts KlotoDx’s opportunity to enter the primary care segment in a very disruptive manner.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "KLOTODX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "KLOTODX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat